Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Diabetes

  Free Subscription


11.05.2026

1 Am J Clin Nutr
2 Am J Ophthalmol
1 Atherosclerosis
1 BMC Pediatr
1 BMJ
2 Br J Ophthalmol
4 Diabet Med
1 Diabetes
4 Diabetes Care
30 Diabetes Obes Metab
2 Diabetologia
1 Invest Ophthalmol Vis Sci
1 J Clin Endocrinol Metab
1 Metabolism
1 Nutr Metab (Lond)
1 Ophthalmol Retina
1 Pediatrics
2 PLoS One


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Clin Nutr

  1. ALESSA HB, Xia T, Mousavi SM, Sawicki C, et al
    Optimal Measures of Carbohydrate Quality to Lower the Risk of Type 2 Diabetes: Findings from Three Prospective Cohort Studies.
    Am J Clin Nutr. 2026 Apr 30:101337. doi: 10.1016/j.ajcnut.2026.101337.
    PubMed         Abstract available


    Am J Ophthalmol

  2. KRZYWICKI T, Engin CD, Grzybowski A
    AUTO MACHINE LEARNING FOR DIABETIC RETINOPATHY SCREENING: A HEAD-TO-HEAD MULTI-PLATFORM COMPARISON AGAINST HUMAN GRADERS AND IDX-DR.
    Am J Ophthalmol. 2026 May 2:S0002-9394(26)00227.
    PubMed         Abstract available

  3. ABDELAAL A, Serhan HA, Alsaadi M, AbouJabal K, et al
    Metformin Use and Risk of Glaucoma: A Systematic Review and Meta-analysis.
    Am J Ophthalmol. 2026 Mar 9:S0002-9394(26)00129.
    PubMed         Abstract available


    Atherosclerosis

  4. ZHANG Y, Nguyen NQH, Hanson PA, Sevilla-Gonzalez M, et al
    Plasma metabolomic profiles associated with cardiovascular disease in type 2 diabetes from the Trans-Omics for Precision Medicine (TOPMed) program.
    Atherosclerosis. 2026;417:120758.
    PubMed         Abstract available


    BMC Pediatr

  5. ILKHANIPOOR H, Hosseini N, Barzegar H, Moravej H, et al
    Assessment of parental awareness of diabetic ketoacidosis in children with diabetes: a cross-sectional study at a tertiary referral center in Iran.
    BMC Pediatr. 2026 May 2. doi: 10.1186/s12887-026-06956.
    PubMed         Abstract available


    BMJ

  6. VALABHJI J, Theodoraki A, Hope D
    Diabetic peripheral neuropathy: the broader complication burden.
    BMJ. 2026;393:s854.
    PubMed        


    Br J Ophthalmol

  7. RUIZ BILBAO S, Mas Casals A, Gomez Sanchez S, Diaz-Aljaro P, et al
    Cost-effectiveness of OCT-enhanced screening for diabetic retinopathy: a 50-year Markov model analysis in type 2 diabetes.
    Br J Ophthalmol. 2026 May 5:bjo-2025-327884. doi: 10.1136/bjo-2025-327884.
    PubMed         Abstract available

  8. FRASER-BELL S, Lee NS, Hashimoto Y, Pollreisz A, et al
    Outcomes of eyes with persistent diabetic macular oedema: The Fight Retinal Blindness! Project.
    Br J Ophthalmol. 2026 May 6:bjo-2025-328621. doi: 10.1136/bjo-2025-328621.
    PubMed         Abstract available


    Diabet Med

  9. CAMARGO TM, Siqueira BA, Marques LFA, Mello LS, et al
    The burden of COVID-19 in hospitalized people with diabetes mellitus in Brazil: Insights from four years of the pandemic.
    Diabet Med. 2026 May 5:e70349. doi: 10.1111/dme.70349.
    PubMed         Abstract available

  10. ZHANG H, Li K, Luo D, Wu Y, et al
    'Dancing with diabetes': Family coping strategies to promote psychological and behavioural adaptation in older children and adolescents with type 1 diabetes-A qualitative study.
    Diabet Med. 2026 May 4:e70348. doi: 10.1111/dme.70348.
    PubMed         Abstract available

  11. CABA M, Speight J, Glab A, Highton P, et al
    A qualitative study exploring and understanding the experiences and unmet needs of adults with type 2 diabetes and diabetes-related foot ulcers.
    Diabet Med. 2026 May 4:e70343. doi: 10.1111/dme.70343.
    PubMed         Abstract available

  12. TROTT M, Pardhan S
    Associations between diabetic retinopathy and modifiable risk factors: Correction based on updated information.
    Diabet Med. 2026 May 4:e70353. doi: 10.1111/dme.70353.
    PubMed        


    Diabetes

  13. SORUM NE, Warnoe J, Holst JJ, Hartmann B, et al
    The Glucagonotropic Effect of GIP Is Negated During Insulin-Induced Hypoglycemia in Type 1 Diabetes: A Randomized, Placebo-Controlled, Crossover Study.
    Diabetes. 2026 May 5:db251128. doi: 10.2337/db25-1128.
    PubMed         Abstract available


    Diabetes Care

  14. WEBER D, Modeste J, Peeling S, Foster TP, et al
    Low-Dose Antithymocyte Globulin in Type 1 Diabetes: Real-World Exploratory Observation of C-Peptide by Modified Quantitative Response (mQR).
    Diabetes Care. 2026 May 5:dc260223. doi: 10.2337/dc26-0223.
    PubMed         Abstract available

  15. PARK S, Cho SH, Kim S, Park SH, et al
    High-Amplitude and Prolonged Glucose Excursions as a Key Determinant of Discordance Between Glucose Management Indicator and Glycated Hemoglobin in Type 1 Diabetes.
    Diabetes Care. 2026 May 4:dc252820. doi: 10.2337/dc25-2820.
    PubMed         Abstract available

  16. TALL S, Pettersson J, Harkonen T, Virtanen SM, et al
    COVID-19 Vaccinations, SARS-CoV-2 Infections, and Type 1 Diabetes in Finnish Children.
    Diabetes Care. 2026 May 5:dc252913. doi: 10.2337/dc25-2913.
    PubMed         Abstract available

  17. TEMPLEMAN EL, Thomas N, Martin S, Wherett DK, et al
    Accounting for Age-Related Increases in HbA1c More Accurately Quantifies Risk of Type 1 Diabetes Progression in Islet Autoantibody-Positive Adults.
    Diabetes Care. 2026 May 6:dc260446. doi: 10.2337/dc26-0446.
    PubMed         Abstract available


    Diabetes Obes Metab

  18. KENNIS VCW, van Riel NAW
    SemaGBA: A System Dynamics Model of the Semaglutide-Responsive Gut-Brain Axis A Model of How the Brain and Semaglutide Regulate Appetite and Weight.
    Diabetes Obes Metab. 2026;28:5184-5194.
    PubMed         Abstract available

  19. CONNERY L, Rosenstock J, Rasouli N, Cheng AYY, et al
    Glycaemic Control According to the Final Insulin Dose Using an Innovative Fixed-Dose Titration of Weekly Insulin Efsitora in Insulin-Naive Type 2 Diabetes.
    Diabetes Obes Metab. 2026 May 3. doi: 10.1111/dom.70814.
    PubMed         Abstract available

  20. SAHAY R, Gowda A, Singh MK, Rao AG, et al
    Sitagliptin, Metformin and Glimepiride Fixed-Dose Combination Compared to Co-Administration of Metformin and High-Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double-Blind, Double-Dummy, Phase 3 Clinical Study.
    Diabetes Obes Metab. 2026 May 3. doi: 10.1111/dom.70778.
    PubMed         Abstract available

  21. ISHIBASHI R, Tatsumi T, Koshizaka M, Takatsuna Y, et al
    Ophthalmic Backgrounds Influencing the Efficacy of SGLT2 Inhibitor in Diabetic Macular Oedema: Post-hoc Analysis of the COMET Trial.
    Diabetes Obes Metab. 2026 May 3. doi: 10.1111/dom.70831.
    PubMed        

  22. ARREDOUANI A
    Type 2 Diabetes and the Glucagon Renaissance: Restoring Bihormonal Equilibrium.
    Diabetes Obes Metab. 2026 May 3. doi: 10.1111/dom.70826.
    PubMed        

  23. YANG Q, Zhao L, Ma J, Ji S, et al
    Kidney Effects of Finerenone Added to Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Diabetic Kidney Disease.
    Diabetes Obes Metab. 2026 May 3. doi: 10.1111/dom.70821.
    PubMed         Abstract available

  24. BAE J, Lee M, Kim HW, Park JT, et al
    Effectiveness and Safety of Finerenone in Patients With Diabetic Kidney Disease: A Real-World Observational Study.
    Diabetes Obes Metab. 2026 May 4. doi: 10.1111/dom.70816.
    PubMed         Abstract available

  25. LIU X, Pan B, Xia D, He X, et al
    Pharmacological Treatment for Gestational Diabetes Mellitus: A Systematic Review and Network Meta-Analysis of 71 Randomised Controlled Trial.
    Diabetes Obes Metab. 2026 May 4. doi: 10.1111/dom.70823.
    PubMed         Abstract available

  26. CHEN L, Yang J, Wang L, Fu A, et al
    Distinct Motivational Profiles Based on Self-Determination Theory Among Young and Middle-Aged Adults With Prediabetes: Associations With Self-Management.
    Diabetes Obes Metab. 2026;28:5195-5207.
    PubMed         Abstract available

  27. NANNA MG, Mena-Hurtado C, Divino V, Zhao Z, et al
    Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real-World: Results From the SCORE-Clinical ASCVD Study.
    Diabetes Obes Metab. 2026;28:4975-4990.
    PubMed         Abstract available

  28. SHAH E, AlShiab R, Abdo A, Ozbek L, et al
    Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP-1 Receptor Agonists.
    Diabetes Obes Metab. 2026;28:4546-4558.
    PubMed         Abstract available

  29. EISA N, Barood O
    Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
    Diabetes Obes Metab. 2026;28:4818-4827.
    PubMed         Abstract available

  30. BESSELL E, Picone T, Markovic T, Sainsbury A, et al
    Does Weight Loss Translate to Workplace Gains? Results of an Employment Questionnaire in Adults With Prediabetes and Overweight or Obesity.
    Diabetes Obes Metab. 2026;28:5001-5010.
    PubMed         Abstract available

  31. VIENGHIRUN J, Sawangjit R, Suttiruksa S, Chaiyakunapruk N, et al
    GLP-1 Receptor/Dual Agonists for Weight Loss: A Systematic Review and Network Meta-Analysis of RCTs.
    Diabetes Obes Metab. 2026;28:5043-5057.
    PubMed         Abstract available

  32. JENDLE J, Norgaard K, Pimia E, Bratke H, et al
    Cost-Effectiveness of Automated Insulin Delivery Systems in Paediatrics, T1D and T2D Adults Across Four Nordic Countries.
    Diabetes Obes Metab. 2026;28:4784-4794.
    PubMed         Abstract available

  33. HAN S, Yang Y, Liu Z, Liu Y, et al
    Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Psychiatric Disorders: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
    Diabetes Obes Metab. 2026;28:5011-5019.
    PubMed         Abstract available

  34. ZENG Q, Ni J, Zhang Z, Cai J, et al
    Advances in Electrocardiogram-Based Non-Invasive Blood Glucose Monitoring Technology.
    Diabetes Obes Metab. 2026;28:4445-4463.
    PubMed         Abstract available

  35. GASOYAN H, Schulte R, Boyer CB, Casacchia NJ, et al
    Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide.
    Diabetes Obes Metab. 2026;28:4795-4805.
    PubMed         Abstract available

  36. HWANG I, Kim Y, Lee SW
    Association of GLP-1 Receptor Agonists With Hepatic Decompensation in the All of Us Research Program.
    Diabetes Obes Metab. 2026;28:4837-4846.
    PubMed         Abstract available

  37. BANERJEE M, Dutta S, Dasgupta S
    Pre-Pregnancy GLP-1 Receptor Agonist or Tirzepatide Use and Gestational Diabetes Risk: Evaluating Pharmacodynamic Carry-Over Versus Post-Discontinuation Metabolic Rebound in a Multinational Federated Cohort.
    Diabetes Obes Metab. 2026 May 7. doi: 10.1111/dom.70853.
    PubMed         Abstract available

  38. KHACHATUROV M, Goulis DG
    Beyond GLP-1 Monotherapy: Novel Multi-Agonists, Amylin Analogues, and Combination Strategies in Obesity and Type 2 Diabetes.
    Diabetes Obes Metab. 2026 May 7. doi: 10.1111/dom.70822.
    PubMed         Abstract available

  39. TENTOLOURIS A, Filippatos C, Tepetes NI, Gavriatopoulou M, et al
    GLP-1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity-Matched Real-World Analysis.
    Diabetes Obes Metab. 2026 May 6. doi: 10.1111/dom.70841.
    PubMed         Abstract available

  40. JIAO J, Wu T, Li F, Yang S, et al
    Associations of Visceral Obesity Indices and Risk of Mild Cognitive Impairment in Patients With Diabetes: A Retrospective Cohort Study.
    Diabetes Obes Metab. 2026 May 6. doi: 10.1111/dom.70832.
    PubMed         Abstract available

  41. WILLIS HJ, Gustafson SK, JaKa MM
    Glycaemic Metrics Improve Significantly Within 7 Days of Continuous Glucose Monitoring Initiation in Non-Insulin-Using People With Type 2 Diabetes.
    Diabetes Obes Metab. 2026 May 6. doi: 10.1111/dom.70815.
    PubMed        

  42. CAKLILI OT, Haymana C, Demirci I, Kebapci MN, et al
    Suboptimal LDL-Cholesterol Control Under the 2019 ESC/EAS Dyslipidemia Guidelines: Results From the Nationwide TEMD-2 Study in Type 2 Diabetes.
    Diabetes Obes Metab. 2026 May 6. doi: 10.1111/dom.70806.
    PubMed         Abstract available

  43. PALERMO L, Senga J, Fakembe P, Zhu X, et al
    Barriers and Enablers to Diabetes Technologies Use Among Individuals With Type 1 Diabetes: A Scoping Review.
    Diabetes Obes Metab. 2026 May 5. doi: 10.1111/dom.70819.
    PubMed         Abstract available

  44. TAN RJL, Ahuja A, Shrestha A, Gallen G, et al
    Variability in Diagnosis of Gastroparesis in Type 1 Diabetes: A Need for a National Screening Programme.
    Diabetes Obes Metab. 2026 May 5. doi: 10.1111/dom.70855.
    PubMed        

  45. MIYATSUKA T, Brash J, Davies E, de Laguiche E, et al
    Adherence and Persistence Among Individuals Living With Type 2 Diabetes and Using a Free Combination of Basal Insulin and an Injectable Glucagon-Like Peptide-1 Receptor Agonist Versus a Fixed-Ratio Combination Therapy: A Japanese Database Study.
    Diabetes Obes Metab. 2026 May 5. doi: 10.1111/dom.70812.
    PubMed         Abstract available

  46. AL RAWASHDH N, Patel BV, Wang SM, Zur RM, et al
    Cost-Effectiveness of Control-IQ+ Technology in Insulin-Treated Patients With Type 2 Diabetes in the United States.
    Diabetes Obes Metab. 2026 May 5. doi: 10.1111/dom.70759.
    PubMed         Abstract available

  47. WANG Y, Zhou Y, Zhu M, Wang X, et al
    Efficacy and Safety of T Cell-Targeted Immunotherapy in Newly Diagnosed Type 1 Diabetes: A Systematic Review and Meta-Analysis.
    Diabetes Obes Metab. 2026 May 4. doi: 10.1111/dom.70829.
    PubMed         Abstract available


    Diabetologia

  48. KANG S, Maya N, Morillo M, Outar M, et al
    Deep learning-powered quantification of endocrine cells and CD3(+) T cells in the natural history of type 1 diabetes.
    Diabetologia. 2026 May 7. doi: 10.1007/s00125-026-06742.
    PubMed         Abstract available

  49. ERDEM N, Arribas-Layton D, Zook HN, O'Meally D, et al
    Human pancreatic ductal cells from non-diabetic donors function as non-professional antigen-presenting cells upon inflammatory cytokine exposure.
    Diabetologia. 2026 May 7. doi: 10.1007/s00125-026-06746.
    PubMed         Abstract available


    Invest Ophthalmol Vis Sci

  50. TORM MEW, Johannesen J, Gardner TW, Hajari JN, et al
    Retinal Neurophysiological Parameters in Young Patients With Type 1 Diabetes.
    Invest Ophthalmol Vis Sci. 2026;67:3.
    PubMed         Abstract available


    J Clin Endocrinol Metab


  51. Correction to: "Automated insulin delivery in young children with type 1 diabetes: a systematic review and meta-analysis".
    J Clin Endocrinol Metab. 2026 May 6:dgag191. doi: 10.1210.
    PubMed        


    Metabolism

  52. GIOSUE A, Skantze V, Testa R, D'Abbronzo G, et al
    Postprandial glucose profiles may reflect heterogeneity in insulin secretion and sensitivity in type 2 diabetes.
    Metabolism. 2026;181:156626.
    PubMed         Abstract available


    Nutr Metab (Lond)

  53. BAHADORAN Z, Norouzirad R, Jeddi S, Ghasemi A, et al
    Higher salivary nitrite is associated with improved glycemic control and insulin sensitivity in patients with type 2 diabetes.
    Nutr Metab (Lond). 2026 May 5. doi: 10.1186/s12986-026-01104.
    PubMed         Abstract available


    Ophthalmol Retina

  54. JOO JH, Zhao AH, Chalasani M, Allan KC, et al
    Impact of Glucagon-like Peptide-1 Receptor Agonists on Age-Related Macular Degeneration at a Tertiary Ophthalmology Center.
    Ophthalmol Retina. 2025 Dec 22:S2468-6530(25)00595.
    PubMed         Abstract available


    Pediatrics

  55. SCHWARZ CR, Vilsboll T, Aistrup MO, Kloppenborg JT, et al
    Effects of Semaglutide on Weight and Insulin Requirements in Two Adolescents With Type 1 Diabetes.
    Pediatrics. 2026 May 8:e2025074286. doi: 10.1542/peds.2025-074286.
    PubMed         Abstract available


    PLoS One

  56. FENG S, He W, Jiang L, Chen M, et al
    A new extended belief rule base method based on neighborhood covering reduction for diabetes diagnosis.
    PLoS One. 2026;21:e0347303.
    PubMed         Abstract available

  57. VERSTER F, Bowden N, Schluter PJ, Chepulis L, et al
    Life expectancy and mortality of people with and without diabetes in Aotearoa | New Zealand: A national cohort study.
    PLoS One. 2026;21:e0345892.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum